PRVA Stock Analysis: Privia Health | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 2.518m USD | 12M Return: -17% | US74276R1023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.7M
EPS Trend: 25.5%
Qual. Beats: 0
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Privia Health Group (NASDAQ: PRVA) is a national physician-enablement company that partners with physician practices, health plans, and health systems to support value-based care delivery. Founded in 2007 and headquartered in Arlington, Virginia, the company went public in April 2021 and operates as a mid-cap stock in the Health Care Services sub-industry.
The companys platform combines a single-TIN medical group, a management services organization (MSO), an accountable care organization (ACO), and a payer/purchaser network, along with technology and population health tools designed to reduce administrative burden on providers. This multi-pronged model allows Privia to align financial incentives across stakeholders while helping providers participate in value-based care arrangements, a growing segment of the U.S. healthcare system that ties reimbursement to quality and cost outcomes rather than fee-for-service volume.
- Implemented lives growth accelerates care management fee revenue
- Medicare ACO shared savings performance drives upside
- Competition from Agilon and other VBC enablers intensifies
- Capital allocation pivots toward share repurchases
| Net Income: 28.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -7.22 > 1.0 |
| NWC/Revenue: 16.6k% < 20% (prev 18.32%; Δ 16.6k% < -1%) |
| CFO/TA -0.00 > 3% & CFO -47.0m > Net Income 28.1m |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131.8m) vs 12m ago 2.63% < -2% |
| Gross Margin: 7.61% > 18% (prev 9.83%; Δ -2.22% > 0.5%) |
| Asset Turnover: 0.32% > 50% (prev 149.3%; Δ -149.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.26 (Total Current Assets 1025b - Total Current Liabilities 634b) / Total Assets 1489b |
| B: -0.10 (Retained Earnings -144b / Total Assets 1489b) |
| C: 0.00 (EBIT TTM 56.1m / Avg Total Assets 745b) |
| D: 1.20 (Book Value of Equity 782b / Total Liabilities 651b) |
| Altman-Z'' = 2.67 = A |
| DSRI: 3.0 (Receivables 574b/444.0m, Revenue 2.36b/1.90b) |
| GMI: 1.29 (GM 9.83% / 7.61%) |
| AQI: 1.02 (AQ_t 0.31 / AQ_t-1 0.30) |
| SGI: 1.24 (Revenue 2.36b / 1.90b) |
| TATA: 0.00 (NI 28.1m - CFO -47.0m) / TA 1489b) |
| Beneish M = -0.93 (Cap -4..+1) = D |
As of October 03, 2026, the stock is trading at USD 20.30 with a total of 1,166,699 shares traded. Over the past week, the price has changed by +2.99%, over one month by -2.03%, over three months by -25.80% and over the past year by -17.01%.
Current recommended Stop Loss: 19.40 (which is 4.4% or 1.4 ATR below the current price).
Privia Health has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy PRVA.
- StrongBuy: 14
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.5 | 55% |
P/E Trailing = 89.5909
P/E Forward = 17.2712
P/S = 1.0677
P/B = 3.1185
Revenue TTM = 2.36b USD
EBIT TTM = 56.1m USD
EBITDA TTM = 68.2m USD
Long Term Debt = 6.66b USD (estimated: total debt 8.73b - short term 2.07b)
Short Term Debt = 2.07b USD (from shortTermDebt, last quarter)
Debt = 8.74b USD (from shortLongTermDebtTotal, last quarter) + Leases 8.73m
Net Debt = -403b USD (calculated: Debt 8.74b - CCE 412b)
Enterprise Value = 2.52b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM 56.1m / Interest Expense TTM 0.0)
EV/FCF = -52.19x (Enterprise Value 2.52b / FCF TTM -48.2m)
FCF Yield = -1.92% (FCF TTM -48.2m / Enterprise Value 2.52b)
FCF Margin = -2.05% (FCF TTM -48.2m / Revenue TTM 2.36b)
Net Margin = 1.19% (Net Income TTM 28.1m / Revenue TTM 2.36b)
Gross Margin = 7.61% ((Revenue TTM 2.36b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 1.86% (prev 9.44%)
Tobins Q-Ratio = 0.00 (Enterprise Value 2.52b / Total Assets 1489b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 8.74b)
Taxrate = 39.69% (22.3m / 56.1m)
NOPAT = 33.8m (EBIT 56.1m * (1 - 39.69%))
Current Ratio = 1.62 (Total Current Assets 1025b / Total Current Liabilities 634b)
Debt / Equity = 0.01 (Debt 8.74b / totalStockholderEquity, last quarter 782b)
Debt / EBITDA = -5.92k (out of range, set to none) (Net Debt -403b / EBITDA 68.2m)
Debt / FCF = 8.36k (out of range, set to none) (Net Debt -403b / FCF TTM -48.2m)
Total Stockholder Equity = 196b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.00% (Net Income 28.1m / Total Assets 1489b)
RoE = 0.01% (Net Income TTM 28.1m / Total Stockholder Equity 196b)
RoCE = 0.03% (EBIT 56.1m / Capital Employed (Equity 196b + L.T.Debt 6.66b))
RoIC = 0.00% (NOPAT 33.8m / Invested Capital 856b)
WACC = 1.72% (E(2.52b)/V(11.3b) * Re(7.71%) + D(8.74b)/V(11.3b) * Rd(0.0%) * (1-Tc(0.40)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.05 | Cagr: 2.37%
[DCF] Fair Price = unknown (Cash Flow -48.2m)
EPS Correlation: 25.51 | EPS CAGR: 4.21% | SUE: -0.25 | # QB: 0
Revenue Correlation: 96.42 | Revenue CAGR: 15.03% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.24 | Chg30d=+0.87% | Revisions=+8% | Analysts=9
EPS current Year (2026-12-31): EPS=0.88 | Chg30d=+0.94% | Revisions=-31% | GrowthEPS=-10.7% | GrowthRev=+15.7%
EPS next Year (2027-12-31): EPS=1.06 | Chg30d=-0.23% | Revisions=+0% | GrowthEPS=+20.0% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: -9% (up=13, down=16)